Viewing nowPregabalin Capsule 25 mg (Pregabalin)
Pregabalin 25mg
Hard capsule · Prescription medication
Hanin Pharmaceutical Co., Ltd.

MFDS item code 201804149 · Approved 2018.10.22 · Insurance code 657203400
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It also helps in the adjunctive treatment of partial seizures in patients with epilepsy. It is effective in improving symptoms in patients with fibromyalgia. It is utilized for a variety of neurological disorders, enhancing patients' quality of life.
This medication is administered orally, regardless of food, as pregabalin in a total daily dose divided into 2 doses. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to “5. Patients with Renal Impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (Refer to “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg ∼ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys unchanged. Since the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (ml/min)* *: For women, multiply the result obtained from the above equation by 0.85. This medication is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a : The total daily dose (mg/day) should be divided as specified in the dosing regimen. b : The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ∼ 17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behaviors, so if there are any changes in mood or behavior during treatment, consulting a physician immediately is advised. Patients with allergic reactions to this medication should not use it. Diabetic patients need to be cautious as weight gain may complicate blood sugar control, and if signs of angioedema appear, they should discontinue use immediately. Elderly patients should be particularly careful at the start of treatment due to a higher risk of dizziness or drowsiness leading to falls. Blurred vision or changes in eyesight may occur; if such symptoms appear, consultation with a physician is necessary. Abrupt discontinuation of this medication may result in withdrawal symptoms like insomnia, headache, anxiety, and depression, so it should be reduced gradually under physician’s guidance. There is a risk of drug abuse; thus, patients with a history of substance abuse should use caution, and any signs of misuse should be reported immediately. Patients with impaired kidney function may require dose adjustments. Patients with heart disease need to use caution while taking this medication. When taken with opioid analgesics, there may be an increased risk of central nervous system depression, so care is needed. Patients with respiratory disease or elderly individuals are at risk of severe respiratory depression and should adjust the dosage according to a physician's guidance. In early pregnancy, there is a risk of fetal malformations, hence women who are pregnant or planning to become pregnant must consult a physician before use and should use effective contraception. Breastfeeding women should consult a physician regarding whether to discontinue breastfeeding or this medication since it can be passed into breast milk. Caution is recommended while driving or operating machinery due to dizziness and drowsiness, and one should be aware of symptoms appearing before engaging in such tasks. In case of severe skin rashes or allergy symptoms, the use should be immediately stopped and medical help should be sought. Overdosing may result in confusion, drowsiness, and seizures, which require immediate emergency treatment. Keep this medication out of reach of children, and avoid transferring it to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is essential to maintain a storage temperature between 15°C and 30°C. This helps to preserve the medication's efficacy and safety.
A hard capsule with a light yellowish upper part and a white lower part containing white or light yellowish powder.
30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 25mg
Hard capsule · Prescription medication
Hanin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.